ClearPoint Neuro (CLPT)
Market Price (7/13/2026): $17.5 | Market Cap: $517.1 MilSector: Health Care | Industry: Life Sciences Tools & Services
ClearPoint Neuro (CLPT)
Market Price (7/13/2026): $17.5Market Cap: $517.1 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -26 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -65% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 21% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -63%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -66% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.8% High stock price volatilityVol 12M is 105% Key risksCLPT key risks include [1] a heavy dependence on the regulatory and commercial success of its drug delivery partners' therapies, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -26 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -65% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 21% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -63%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -66% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.8% |
| High stock price volatilityVol 12M is 105% |
| Key risksCLPT key risks include [1] a heavy dependence on the regulatory and commercial success of its drug delivery partners' therapies, Show more. |
Qualitative Assessment
AI Analysis | Feedback
ClearPoint Neuro (CLPT) stock has gained about 90% since 3/31/2026 because of the following key factors:
1. Significant Regulatory Progress for a Key Partner's Gene Therapy: ClearPoint Neuro's stock experienced a substantial surge, reportedly gaining 50% on June 17, 2026, after its partner, uniQure, announced that the U.S. Food and Drug Administration (FDA) agreed that three-year Phase I/II trial data for AMT-130, a gene therapy for Huntington's disease, would be sufficient to support a Biologics License Application (BLA) for accelerated approval. This is a critical development for ClearPoint Neuro as AMT-130 is administered using the company's navigation system and SmartFlow cannula, indicating a potential for significant commercial opportunity for its core technology in gene therapy delivery. UniQure plans to submit the BLA in fiscal Q3 2026.
2. Strong Fiscal Q1 2026 Revenue Growth Exceeding Estimates: ClearPoint Neuro reported robust financial results for fiscal Q1 2026 (ended March 31, 2026), with revenue reaching $12.1 million. This exceeded analyst estimates of $11.97 million and represented a 43% year-over-year overall growth, including 16% total organic growth compared to fiscal Q1 2025. The growth was particularly strong in key segments, with neurosurgery navigation, therapy, and access revenue increasing by 80% to $5.9 million and capital equipment and software revenue surging by 177% to $1.4 million.
Show more
ClearPoint Neuro (CLPT) stock has gained about 90% since 3/31/2026 because of the following key factors:
1. Significant Regulatory Progress for a Key Partner's Gene Therapy: ClearPoint Neuro's stock experienced a substantial surge, reportedly gaining 50% on June 17, 2026, after its partner, uniQure, announced that the U.S. Food and Drug Administration (FDA) agreed that three-year Phase I/II trial data for AMT-130, a gene therapy for Huntington's disease, would be sufficient to support a Biologics License Application (BLA) for accelerated approval. This is a critical development for ClearPoint Neuro as AMT-130 is administered using the company's navigation system and SmartFlow cannula, indicating a potential for significant commercial opportunity for its core technology in gene therapy delivery. UniQure plans to submit the BLA in fiscal Q3 2026.
2. Strong Fiscal Q1 2026 Revenue Growth Exceeding Estimates: ClearPoint Neuro reported robust financial results for fiscal Q1 2026 (ended March 31, 2026), with revenue reaching $12.1 million. This exceeded analyst estimates of $11.97 million and represented a 43% year-over-year overall growth, including 16% total organic growth compared to fiscal Q1 2025. The growth was particularly strong in key segments, with neurosurgery navigation, therapy, and access revenue increasing by 80% to $5.9 million and capital equipment and software revenue surging by 177% to $1.4 million.
3. Expansion of Product Portfolio and Global Market Access: The company bolstered its product offerings and global reach through several strategic regulatory clearances and partnerships. In April 2026, ClearPoint Neuro received FDA 510(k) clearance for its Velocity Alpha MR High Speed Surgical Drill System, which then saw its first clinical use, expanding the company's capabilities for complex neurosurgical procedures. Additionally, in April 2026, the company secured a Medical Device License from Health Canada for its Neuro Navigation System, and in May 2026, it entered into a 10-year focused ultrasound development partnership with Sungkyunkwan University in South Korea, further broadening its technology ecosystem and market penetration.
4. Increased Analyst Confidence and Upgraded Price Targets: Following the positive company-specific news, particularly the FDA feedback for partner uniQure's AMT-130, analyst sentiment turned more bullish. B. Riley Securities, for instance, responded by raising its price target for ClearPoint Neuro to $30 from $20. Lake Street also reiterated a "Buy" rating for the stock with a $30 price target, signaling growing analyst optimism about the company's future prospects.
Show less
Stock Movement Drivers
Fundamental Drivers
The 92.3% change in CLPT stock from 3/31/2026 to 7/12/2026 was primarily driven by a 79.3% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.10 | 17.50 | 92.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 37 | 41 | 9.9% |
| P/S Multiple | 7.1 | 12.7 | 79.3% |
| Shares Outstanding (Mil) | 29 | 30 | -2.4% |
| Cumulative Contribution | 92.3% |
Market Drivers
3/31/2026 to 7/12/2026| Return | Correlation | |
|---|---|---|
| CLPT | 92.3% | |
| Market (SPY) | 16.1% | 17.5% |
| Sector (XLV) | 9.7% | 15.0% |
Fundamental Drivers
The 27.9% change in CLPT stock from 12/31/2025 to 7/12/2026 was primarily driven by a 18.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.68 | 17.50 | 27.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 34 | 41 | 18.3% |
| P/S Multiple | 11.3 | 12.7 | 12.4% |
| Shares Outstanding (Mil) | 28 | 30 | -3.8% |
| Cumulative Contribution | 27.9% |
Market Drivers
12/31/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| CLPT | 27.9% | |
| Market (SPY) | 11.0% | 27.7% |
| Sector (XLV) | 4.3% | 21.8% |
Fundamental Drivers
The 46.6% change in CLPT stock from 6/30/2025 to 7/12/2026 was primarily driven by a 26.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.94 | 17.50 | 46.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 41 | 26.0% |
| P/S Multiple | 10.3 | 12.7 | 24.0% |
| Shares Outstanding (Mil) | 28 | 30 | -6.2% |
| Cumulative Contribution | 46.6% |
Market Drivers
6/30/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| CLPT | 46.6% | |
| Market (SPY) | 23.2% | 24.0% |
| Sector (XLV) | 20.9% | 15.7% |
Fundamental Drivers
The 141.7% change in CLPT stock from 6/30/2023 to 7/12/2026 was primarily driven by a 93.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.24 | 17.50 | 141.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 21 | 41 | 93.8% |
| P/S Multiple | 8.5 | 12.7 | 49.9% |
| Shares Outstanding (Mil) | 25 | 30 | -16.8% |
| Cumulative Contribution | 141.7% |
Market Drivers
6/30/2023 to 7/12/2026| Return | Correlation | |
|---|---|---|
| CLPT | 141.7% | |
| Market (SPY) | 76.3% | 35.7% |
| Sector (XLV) | 26.9% | 27.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CLPT Return | -29% | -25% | -20% | 127% | -11% | 31% | 13% |
| Peers Return | 6% | -8% | 11% | 14% | 6% | -19% | 6% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| CLPT Win Rate | 25% | 33% | 42% | 50% | 50% | 57% | |
| Peers Win Rate | 48% | 48% | 52% | 58% | 53% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| CLPT Max Drawdown | -62% | -53% | -58% | -33% | -58% | -45% | |
| Peers Max Drawdown | -22% | -29% | -20% | -14% | -16% | -33% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, ZBH, SYK, ABT, BSX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/10/2026 (YTD)
How Low Can It Go
| Event | CLPT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.3% | -18.8% |
| % Gain to Breakeven | 70.4% | 23.1% |
| Time to Breakeven | 169 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -10.9% | -7.8% |
| % Gain to Breakeven | 12.3% | 8.5% |
| Time to Breakeven | 1 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.6% | -9.5% |
| % Gain to Breakeven | 46.2% | 10.5% |
| Time to Breakeven | 26 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.4% | -6.7% |
| % Gain to Breakeven | 43.6% | 7.1% |
| Time to Breakeven | 403 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -38.9% | -24.5% |
| % Gain to Breakeven | 63.6% | 32.4% |
| Time to Breakeven | 22 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -45.2% | -33.7% |
| % Gain to Breakeven | 82.4% | 50.9% |
| Time to Breakeven | 170 days | 140 days |
In The Past
ClearPoint Neuro's stock fell -41.3% during the 2025 US Tariff Shock. Such a loss loss requires a 70.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CLPT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.3% | -18.8% |
| % Gain to Breakeven | 70.4% | 23.1% |
| Time to Breakeven | 169 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.6% | -9.5% |
| % Gain to Breakeven | 46.2% | 10.5% |
| Time to Breakeven | 26 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.4% | -6.7% |
| % Gain to Breakeven | 43.6% | 7.1% |
| Time to Breakeven | 403 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -38.9% | -24.5% |
| % Gain to Breakeven | 63.6% | 32.4% |
| Time to Breakeven | 22 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -45.2% | -33.7% |
| % Gain to Breakeven | 82.4% | 50.9% |
| Time to Breakeven | 170 days | 140 days |
In The Past
ClearPoint Neuro's stock fell -41.3% during the 2025 US Tariff Shock. Such a loss loss requires a 70.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About ClearPoint Neuro (CLPT)
ClearPoint Neuro, Inc. (CLPT) is a medical device company specializing in advanced neurosurgical solutions. The company develops and commercializes sophisticated platforms designed to perform minimally invasive surgical procedures within the brain. A key differentiator of their technology is the ability to conduct these procedures under direct, intra-procedural Magnetic Resonance Imaging (MRI) guidance, enhancing precision and safety during delicate brain operations.
The company's core product is the ClearPoint system, a versatile platform with multiple critical applications. This system facilitates the accurate insertion of deep brain stimulation electrodes, precise biopsy needles for tissue sampling, and the controlled infusion of pharmaceuticals directly into the brain. Additionally, it supports the placement of laser catheters for various therapeutic interventions. Complementing this, ClearPoint Neuro also offers the ClearPoint Neuro Navigation System, an integrated MRI suite component that enables the real-time imaging and guidance central to their procedural approach.
ClearPoint Neuro primarily serves the medical market within the United States, targeting institutions and neurosurgeons who require advanced, image-guided solutions for brain procedures. Their customer base includes hospitals and specialized clinics performing complex neurosurgeries, particularly those focused on deep brain stimulation, targeted drug delivery, and minimally invasive diagnostic or therapeutic interventions. The company also maintains strategic license and collaboration agreements with prominent medical technology firms and universities, further integrating their systems into leading-edge neurological care and research.
AI Analysis | Feedback
1. Imagine an Intuitive Surgical, but exclusively focused on performing minimally invasive brain surgery using real-time MRI guidance instead of robotics.
2. Think of it like a highly specialized Medtronic or Boston Scientific, providing MRI-guided navigation and precision tools specifically for accessing and treating the brain.
AI Analysis | Feedback
- ClearPoint system: A platform designed for minimally invasive surgical procedures in the brain, including the insertion of deep brain stimulation electrodes, biopsy needles, and the infusion of pharmaceuticals and laser catheters, all under direct, intra-procedural MRI guidance.
- ClearPoint Neuro Navigation System: A system specifically designed for use within an MRI suite to aid in surgical navigation.
AI Analysis | Feedback
ClearPoint Neuro (CLPT) primarily sells its advanced medical devices and navigation systems to hospitals, academic medical centers, and surgical centers, which are institutional customers. While these institutions are the primary end-users of its core products, the company also engages in significant business-to-business relationships through licensing and collaboration agreements.
Based on the information provided regarding its license and collaboration agreements, the following public companies are identified as major customers for ClearPoint Neuro's technology, intellectual property, or specialized components/services:
These collaborations suggest a relationship where ClearPoint Neuro provides its proprietary technology, intellectual property, or specialized products and services to these larger medical device and technology companies, generating revenue for CLPT.
AI Analysis | Feedback
AI Analysis | Feedback
Joseph M. Burnett
Chief Executive Officer and President
Joseph M. Burnett joined ClearPoint Neuro as President and Chief Executive Officer and became a member of its Board of Directors in November 2017. Prior to ClearPoint Neuro, Mr. Burnett served as Vice President and General Manager of Neuro Diagnostics and Therapy at Philips from March 2016. He was also the Senior Vice President and Business Leader of Image Guided Therapy Devices at Philips and General Manager of Volcano Corporation (a Philips company) from February 2015 to March 2016. Before joining Philips, Mr. Burnett held various positions at Volcano Corporation from November 2004 to February 2015, including Executive Vice President and General Manager of its Coronary & Systems Business Unit. He also worked as an R&D Engineer and Product Manager at Guidant Corporation from August 1999 to November 2004.
Danilo D'Alessandro
Chief Financial Officer and Principal Accounting Officer
Danilo D'Alessandro joined ClearPoint Neuro as Vice President of Finance in September 2020 and assumed the CFO position on January 1, 2021. He has an extensive background in global corporate finance, financial planning, growth, and mergers & acquisitions (M&A). Before joining ClearPoint Neuro, from April 2015, Mr. D'Alessandro served as the global Head of Finance for the Image Guided Therapy Devices Division at Royal Philips, a business unit representing cumulative inorganic investments of approximately $4 billion. He also held a variety of senior roles at Philips in Finance and M&A in both the United States and the Netherlands.
Jeremy L. Stigall
Chief Business Officer
Jeremy L. Stigall joined ClearPoint Neuro in July 2020 as Vice President, Biologics and Drug Delivery. He became Executive Vice President and General Manager of Biologics & Drug Delivery in December 2022 and then Chief Business Officer in February 2024. Mr. Stigall brings over 20 years of experience in the medical device industry, having started his career at Guidant Corporation and Abbott Vascular in various R&D, Engineering, and Operations positions. He was responsible for the development and commercialization of several key stent delivery systems and drug-eluting stent platforms.
Mazin Sabra
Chief Operating Officer
Mazin Sabra is the Chief Operating Officer at ClearPoint Neuro. He previously served as Vice President of Supplier Quality Engineering for Philips, a multinational health technology company, since April 2021. In this role at Philips, Mr. Sabra led a global team responsible for the quality performance of suppliers for Royal Philips' products, which ranged from Class III medical devices to consumer products. He was also responsible for business procurement strategy, supply risk management, profitability, and growth.
AI Analysis | Feedback
- Dependency on Biopharma Partner Success and Commercialization of Gene/Cell Therapies: ClearPoint Neuro's long-term growth, particularly in its biologics and drug delivery segment, is heavily reliant on the successful development, regulatory approval, and commercialization of therapies by its biopharma partners. The pace of gene and cell therapy commercialization, and the success of these partners' clinical trials, directly impact ClearPoint Neuro's revenue trajectory.
- Profitability and Cash Burn: The company is currently operating at a significant loss, with negative operating and net margins, and has experienced negative free cash flow. While ClearPoint Neuro maintains a cash balance, its ability to achieve consistent profitability and manage its cash burn effectively is a critical financial risk.
- Reimbursement and Regulatory Challenges: ClearPoint Neuro faces challenges related to reimbursement for its procedures, as many are billed under fixed Medicare Part A DRG payments, lacking device-specific reimbursement. Securing new CPT codes or therapy-linked reimbursement frameworks for future commercial drug procedures can be complex and time-consuming. Additionally, FDA review timelines for new products or software modules can delay market entry, and the medical device industry is inherently subject to various regulatory hurdles. Integration challenges from acquisitions, such as IRRAS, also pose risks to anticipated performance.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
ClearPoint Neuro (CLPT) is positioned for future revenue growth over the next 2-3 years, driven by several key initiatives:
- Expansion of Biologics and Drug Delivery Partnerships: ClearPoint Neuro anticipates significant growth from its biologics and drug delivery segment, which includes sales of disposable products and services related to customer-sponsored preclinical and clinical trials. The company's drug delivery platform has shown strong validation through positive clinical data from partners, such as uniQure's Huntington's therapy, which is expected to lead to improved deal economics and an "inflection point" in biopharma revenue as programs for indications like Parkinson's and epilepsy potentially commercialize. Furthermore, the operational launch of ClearPoint Advanced Laboratories, a new preclinical Contract Research Organization (CRO) facility, is expected to increase capacity and enable higher-value GLP (Good Laboratory Practice) studies, thereby contributing to this revenue stream.
- Strategic Acquisition and Integration of IRRAS: The recent acquisition of IRRAS Holdings, Inc., is a crucial driver, projected to create a new market opportunity in neuro drug delivery and enhance ClearPoint Neuro's operational capabilities through an expanded sales team. This acquisition provides immediate market access to a substantial segment through the IRRAflow catheter, with ClearPoint Neuro forecasting that the integration of the IRRAflow product line will contribute to its projected revenue of $54-$60 million by 2026.
- Advancements in Neurosurgery Navigation and Therapy Products: Growth in the neurosurgery navigation and therapy segment is expected, primarily propelled by increased adoption and sales of the ClearPoint PRISM Laser Therapy System and the introduction of new navigation software. The recent FDA 510(k) clearance expanding the PRISM Laser Therapy System's compatibility with 1.5T MRI guidance, in addition to its existing 3T MRI clearance, significantly broadens its market reach by opening up over 50% of the existing neuro laser interstitial thermal therapy (LITT) market. Expected CE Mark approval in Europe for PRISM 1.5T in the second half of 2026 will further extend its market presence.
- Expansion of Installed Base and Global Commercial Footprint: ClearPoint Neuro is focused on expanding its installed base of capital equipment and software, which includes the ClearPoint Neuro Navigation System and PRISM laser units. The company is also actively working to activate new global centers and secure expanded international regulatory approvals in regions such as Canada, Hong Kong, and Taiwan. This strategic global expansion is intended to broaden its commercial reach, support a growing number of cell and gene therapy trials, and prepare for eventual commercialization on a wider scale.
- Development and Introduction of New Product Innovations: ClearPoint Neuro is investing in research and development to bring new innovations to market, such as its prototype Robotic Neuro-Navigation System. This system is being designed to enable the ClearPoint Neuro Navigation software to control robotic arms for various minimally invasive cranial surgical procedures, including cell and gene therapy infusions, laser catheter placement, and deep brain stimulation. Such new product launches are anticipated to be significant catalysts for future revenue growth, broadening the company's product portfolio and addressing unmet needs in neurological care.
AI Analysis | Feedback
Share Issuance
- ClearPoint Neuro issued 1,325,000 shares of its common stock as part of the closing consideration for the acquisition of IRRAS Holdings, Inc. on November 6, 2025.
- On May 12, 2025, the company completed a registered direct offering, selling 275,808 shares at $12.69 each, raising approximately $3.5 million.
- In August 2025, ClearPoint Neuro entered into a stock purchase agreement with Oberland Capital Management for an additional $3.5 million in gross proceeds from the purchase of its common stock.
Inbound Investments
- ClearPoint Neuro entered into a note financing arrangement with Oberland Capital Management for up to $105.0 million, with $30.0 million of gross proceeds funded at closing on August 12, 2025.
- On November 5, 2025, the company arranged access to an additional $20.0 million under its existing note agreement with Oberland Capital, contingent on the IRRAS acquisition closing.
Outbound Investments
- ClearPoint Neuro completed the acquisition of IRRAS Holdings, Inc. on November 6, 2025, for $5.0 million in cash and 1,325,000 shares of its common stock, with potential future earnout payments.
Capital Expenditures
- Capital expenditures for the last 12 months (as of early March 2026) were reported as -$736,000.
- The company's capital expenditures for the year 2024 were $275,000.
- Proceeds from a May 2025 stock offering were intended for general corporate purposes, which included capital expenditures.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 87.61 |
| Mkt Cap | 87.0 |
| Rev LTM | 22,942 |
| Op Inc LTM | 4,614 |
| FCF LTM | 3,934 |
| FCF 3Y Avg | 3,097 |
| CFO LTM | 4,858 |
| CFO 3Y Avg | 3,960 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.0% |
| Rev Chg 3Y Avg | 7.9% |
| Rev Chg Q | 9.6% |
| QoQ Delta Rev Chg LTM | 2.3% |
| Op Inc Chg LTM | 6.2% |
| Op Inc Chg 3Y Avg | 4.9% |
| Op Mgn LTM | 17.9% |
| Op Mgn 3Y Avg | 18.5% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.6% |
| CFO/Rev 3Y Avg | 19.9% |
| FCF/Rev LTM | 16.1% |
| FCF/Rev 3Y Avg | 15.1% |
Price Behavior
| Market Price | $17.50 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 05/21/2012 | |
| Distance from 52W High | -40.9% | |
| 50 Days | 200 Days | |
| DMA Price | $14.01 | $14.84 |
| DMA Trend | up | up |
| Distance from DMA | 24.9% | 17.9% |
| 3M | 1YR | |
| Volatility | 91.0% | 105.3% |
| Downside Capture | 46.79 | 195.82 |
| Upside Capture | 302.20 | 201.32 |
| Correlation (SPY) | 20.9% | 24.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.56 | 0.28 | 1.26 | 1.90 | 2.03 | 2.03 |
| Up Beta | 0.70 | 0.98 | 1.94 | 2.53 | 3.17 | 2.22 |
| Down Beta | 0.27 | -0.55 | -1.66 | -0.36 | 1.08 | 1.93 |
| Up Capture | 108% | 236% | 359% | 384% | 358% | 1316% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 12 | 24 | 37 | 68 | 122 | 353 |
| Down Capture | -314% | -108% | 79% | 190% | 155% | 111% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 9 | 17 | 26 | 56 | 125 | 385 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CLPT | |
|---|---|---|---|---|
| CLPT | 43.1% | 104.9% | 0.78 | - |
| Sector ETF (XLV) | 20.3% | 15.7% | 0.98 | 16.5% |
| Equity (SPY) | 22.1% | 12.5% | 1.31 | 24.2% |
| Gold (GLD) | 23.5% | 27.8% | 0.75 | 12.4% |
| Commodities (DBC) | 23.6% | 18.7% | 0.99 | -6.4% |
| Real Estate (VNQ) | 13.4% | 13.9% | 0.67 | 6.7% |
| Bitcoin (BTCUSD) | -42.5% | 42.8% | -1.17 | 20.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CLPT | |
|---|---|---|---|---|
| CLPT | -2.0% | 78.9% | 0.30 | - |
| Sector ETF (XLV) | 6.5% | 14.9% | 0.25 | 31.6% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 40.1% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 12.0% |
| Commodities (DBC) | 7.3% | 19.5% | 0.27 | 6.1% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.05 | 27.2% |
| Bitcoin (BTCUSD) | 13.8% | 53.4% | 0.44 | 25.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CLPT | |
|---|---|---|---|---|
| CLPT | 19.2% | 78.5% | 0.65 | - |
| Sector ETF (XLV) | 10.3% | 16.6% | 0.51 | 26.9% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 33.6% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | 8.4% |
| Commodities (DBC) | 6.0% | 18.0% | 0.26 | 8.0% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 23.9% |
| Bitcoin (BTCUSD) | 58.6% | 66.2% | 0.99 | 19.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/16/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/13/2026 | 4.8% | -8.1% | 10.3% |
| 3/17/2026 | -13.9% | -15.6% | -5.9% |
| 1/12/2026 | 4.9% | -1.8% | -8.9% |
| 11/6/2025 | -13.3% | -15.0% | -26.3% |
| 8/12/2025 | 13.1% | -0.8% | 5.2% |
| 5/13/2025 | -12.5% | -9.9% | -14.9% |
| 2/26/2025 | -17.5% | -17.7% | -27.9% |
| 11/7/2024 | -13.2% | -16.2% | 9.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 14 |
| # Negative | 14 | 14 | 14 |
| Median Positive | 7.0% | 8.1% | 12.8% |
| Median Negative | -12.8% | -10.5% | -11.9% |
| Max Positive | 40.7% | 52.6% | 84.6% |
| Max Negative | -17.7% | -21.7% | -30.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/13/2026 | 4.8% | -8.1% | 10.3% |
| 3/17/2026 | -13.9% | -15.6% | -5.9% |
| 1/12/2026 | 4.9% | -1.8% | -8.9% |
| 11/6/2025 | -13.3% | -15.0% | -26.3% |
| 8/12/2025 | 13.1% | -0.8% | 5.2% |
| 5/13/2025 | -12.5% | -9.9% | -14.9% |
| 2/26/2025 | -17.5% | -17.7% | -27.9% |
| 11/7/2024 | -13.2% | -16.2% | 9.2% |
| 8/7/2024 | 40.7% | 52.6% | 84.6% |
| 5/7/2024 | 1.7% | 2.0% | -2.5% |
| 3/12/2024 | 18.5% | 15.4% | 2.5% |
| 1/8/2024 | 17.9% | 19.7% | 11.6% |
| 11/9/2023 | -17.7% | -3.0% | 17.7% |
| 8/8/2023 | -2.8% | -6.2% | -18.3% |
| 5/11/2023 | -1.6% | -7.9% | -20.8% |
| 3/1/2023 | -9.8% | -11.0% | -5.9% |
| 1/11/2023 | 2.5% | 7.6% | -3.5% |
| 11/8/2022 | -5.4% | 0.6% | -8.7% |
| 8/9/2022 | 13.6% | 8.6% | -11.8% |
| 5/11/2022 | 9.2% | 22.8% | 60.9% |
| 3/1/2022 | 2.3% | 0.5% | 21.4% |
| 11/9/2021 | -1.5% | -12.0% | -30.3% |
| 8/10/2021 | -16.6% | -21.7% | -12.1% |
| 5/11/2021 | 1.1% | 4.0% | 13.3% |
| 3/4/2021 | -13.6% | 2.1% | 12.1% |
| 1/12/2021 | 2.3% | 27.0% | 64.6% |
| 11/10/2020 | 15.8% | 36.5% | 56.2% |
| 8/12/2020 | -2.2% | 5.0% | 12.3% |
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 14 |
| # Negative | 14 | 14 | 14 |
| Median Positive | 7.0% | 8.1% | 12.8% |
| Median Negative | -12.8% | -10.5% | -11.9% |
| Max Positive | 40.7% | 52.6% | 84.6% |
| Max Negative | -17.7% | -21.7% | -30.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/17/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/17/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/09/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/11/2021 | 10-Q |
| 12/31/2020 | 03/22/2021 | 10-K |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/13/2020 | 10-Q |
| 12/31/2019 | 03/27/2020 | 10-K |
| 09/30/2019 | 11/13/2019 | 10-Q |
| 06/30/2019 | 08/12/2019 | 10-Q |
Recent Forward Guidance
Updated 7/12/2026Latest: Q1 2026 Earnings Reported 5/13/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 52.00 Mil | 54.00 Mil | 56.00 Mil | 0 | Affirmed | Guidance: 54.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 3/17/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 52.00 Mil | 54.00 Mil | 56.00 Mil | -5.3% | Lowered | Guidance: 57.00 Mil for 2026 | |
Q4 2025 Earnings Reported 1/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 54.00 Mil | 57.00 Mil | 60.00 Mil | 0 | Affirmed | Guidance: 57.00 Mil for 2026 | |
Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 36.00 Mil | 37.00 Mil | 38.00 Mil | Affirmed | Guidance: 38.50 Mil for 2025 | ||
| 2026 Combined Revenue | 54.00 Mil | 57.00 Mil | 60.00 Mil | ||||
Insider Activity
Updated 7/6/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Burnett, Joseph | CEO and President | Direct | Sell | 7012026 | 19.38 | 20,000 | 387,600 | 2,264,398 | Form |
| 2 | Burnett, Joseph | CEO and President | Direct | Sell | 6222026 | 17.79 | 60,000 | 1,067,400 | 2,078,619 | Form |
| 3 | Burnett, Joseph | CEO and President | See Footnote | Sell | 6222026 | 17.94 | 1,843 | 33,063 | 3,433,501 | Form |
| 4 | Richards, Timothy T | Direct | Sell | 6022026 | 12.17 | 5,415 | 65,901 | 1,061,200 | Form | |
| 5 | Klein, Matthew B | Direct | Sell | 5262026 | 11.59 | 16,000 | 185,440 | 543,977 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Burnett, Joseph | CEO and President | Direct | Sell | 7012026 | 19.38 | 20,000 | 387,600 | 2,264,398 | Form |
| 2 | Burnett, Joseph | CEO and President | Direct | Sell | 6222026 | 17.79 | 60,000 | 1,067,400 | 2,078,619 | Form |
| 3 | Burnett, Joseph | CEO and President | See Footnote | Sell | 6222026 | 17.94 | 1,843 | 33,063 | 3,433,501 | Form |
| 4 | Richards, Timothy T | Direct | Sell | 6022026 | 12.17 | 5,415 | 65,901 | 1,061,200 | Form | |
| 5 | Klein, Matthew B | Direct | Sell | 5262026 | 11.59 | 16,000 | 185,440 | 543,977 | Form | |
| 6 | Fallon, Lynnette C | Direct | Sell | 5212026 | 11.14 | 5,091 | 56,714 | 537,249 | Form | |
| 7 | Burnett, Joseph | CEO and President | See Footnote | Sell | 2262026 | 15.17 | 19,951 | 302,657 | 2,931,314 | Form |
| 8 | Burnett, Joseph | CEO and President | See Footnote | Sell | 1272026 | 15.57 | 2,943 | 45,823 | 3,333,786 | Form |
| 9 | Burnett, Joseph | CEO and President | Direct | Sell | 1132026 | 16.12 | 20,000 | 322,400 | 186,428 | Form |
| 10 | Burnett, Joseph | CEO and President | See Footnote | Sell | 10142025 | 26.98 | 26,463 | 714,021 | 5,856,652 | Form |
Investor Activity (13F)
Updated Jul 13, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank and community-bank filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Mak Capital One LLC | $17.3 Mil | 2.9% | 21 | New | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Mak Capital One LLC | $17.3 Mil | 2.9% | 21 | New | 13F |
| Active Manager |
|---|
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Mak Capital One LLC | $17.3 Mil | 2.9% | 21 | New | 13F |
ClearPoint Neuro — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.